Powering Advancements in Heart Health
The ability to detect cardiac biomarkers at ultra-low levels is advancing the future of heart health.
Simoa® assays have the potential to detect cardiac biomarkers, which are instrumental for predicting major adverse cardiovascular events, development of heart failure or transition to end-stage kidney disease, earlier than ever before. Further, the ability to detect minute changes in these biomarkers could enable the identification of at-risk patients earlier in their disease progression to guide more personalized, preventive care.
Click through the alphabet to see available assays
Serum neurofilament measurement improves clinical risk scores for outcome prediction after cardiac arrest: results of a prospective study
A recent study found serum neurofilament light chain (NfL) levels to be strongly associated with poor neurological outcome in patients after cardiac arrest. Our aim was to confirm these findings in an independent validation study and to investigate whether NfL improves the prognostic value of two cardiac arrest-specific risk scores.